SCHD vs. NOBL: Different Paths to Dividend Stability

The piece compares Schwab U.S. Dividend Equity ETF (SCHD) and ProShares S&P 500 Dividend Aristocrats ETF (NOBL), highlighting SCHD’s much lower expense ratio (0.06% vs. 0.35%) and higher dividend yield (3.8% vs. 2.0% as of Dec. 16, 2025) alongside larger AUM ($71.15B vs. $11.3B). Over five years NOBL slightly outpaced SCHD in total growth of $1,000 ($1,311 vs. $1,285) but experienced a marginally deeper max drawdown (−17.92% vs. −16.86%); SCHD holds 102 stocks with tilts to energy (20%), consumer defensive (18%), and healthcare (16%), while NOBL holds 70 stocks concentrated in industrials (23%) and consumer defensive (22%). The practical takeaway: SCHD favors higher current income and lower fees via broader eligibility and quality screens, whereas NOBL enforces 25-year dividend-growth rules and equal-weighting for a more concentrated, dividend-growth–focused exposure.

Analysis

Market structure: Lower fees and higher yield make SCHD the likely net beneficiary of incremental passive flows into dividend strategies — its $71B AUM vs NOBL’s $11B and a 3.8% vs 2.0% yield create a clear cash-on-cash advantage that should boost SCHD inflows by mid‑2026 if rates stabilize. Sector tilts matter: SCHD’s ~20% energy/16% healthcare exposure ties its performance to oil and biotech cashflows, while NOBL’s 23% industrials exposure (including cyclical names like ALB) makes it more sensitive to a growth shock.

Risk assessment: Tail risks include a sudden commodity crash that forces energy dividend cuts (hurting SCHD) and a deep recession that forces Aristocrats to pause increases (hurting NOBL). Near-term (days–weeks) expect rebalancing flows around quarter/year ends; medium (3–12 months) rate moves will dictate relative performance as higher rates compress dividend valuations; long-term (1–3 years) company-level payout sustainability matters more than fund fees.

Trade implications: Favor a modest tilt into SCHD vs NOBL to capture fee and yield spread but hedge cyclical exposure — implement a 1:1 long SCHD / short NOBL pair for 6–12 months, size 2–4% of portfolio, stop if relative total-return gap narrows to <50bps. Complement with longs in resilient healthcare/tech payers (AMGN, CSCO) and a short or put-spread on ALB to hedge industrial/materials cyclicality.

Contrarian angles: The market underestimates dividend-growth optionality in NOBL — in severe downturns Aristocrats historically cut less and can outperform; if GDP growth falls <+1% YoY and yields compress, NOBL could re-rate. Overreliance on fee delta (0.29% gap) is likely overdone if sector shocks hit SCHD’s energy book; consider paired hedges rather than unilateral long exposure.

Key Decisions for Investors

• Establish a 3% net long position in SCHD (ticker SCHD) funded by a 2% trim to broad S&P exposure and 1% trim to NOBL; target horizon 9–18 months, exit if SCHD underperforms NOBL by >150 bps over any 3‑month window or SCHD yield falls below 3.2%.
• Put on a 1:1 pair trade long SCHD / short NOBL sized 2% of portfolio for 6–12 months to capture fee + yield spread while neutralizing beta; tighten or close if the pair’s relative TR spread compresses to <50 bps or widens beyond 300 bps (take partial profits at +150 bps).
• Buy a 6‑month put spread on ALB (e.g., put strikes ~10–20% out-of-the-money depending on premium) to hedge industrial/material exposure — risk known premium, payoff if ALB falls >10–15% amid cyclical slowdown.
• Overweight AMGN and CSCO by +1–2% each (replacing cyclical industrials), and reduce direct exposure to EXPD/ALB/other NOBL industrials by 2–3% to lower cyclical drawdown risk over the next 12 months while preserving dividend income.